Literature DB >> 28253385

Association of Steroid 5α-Reductase Type 3 Congenital Disorder of Glycosylation With Early-Onset Retinal Dystrophy.

Rachel L Taylor1, Gavin Arno2, James A Poulter3, Kamron N Khan4, Jiten Morarji5, Sarah Hull6, Nikolas Pontikos7, Antonio Rueda Martin8, Katherine R Smith8, Manir Ali3, Carmel Toomes3, Martin McKibbin4, Jill Clayton-Smith1, Stephanie Grunewald9, Michel Michaelides6, Anthony T Moore10, Alison J Hardcastle6, Chris F Inglehearn3, Andrew R Webster6, Graeme C Black1.   

Abstract

Importance: Steroid 5α-reductase type 3 congenital disorder of glycosylation (SRD5A3-CDG) is a rare disorder of N-linked glycosylation. Its retinal phenotype is not well described but could be important for disease recognition because it appears to be a consistent primary presenting feature. Objective: To investigate a series of patients with the same mutation in the SRD5A3 gene and thereby characterize its retinal manifestations and other associated features. Design, Setting and Participants: Seven affected individuals from 4 unrelated families with early-onset retinal dystrophy as a primary manifestation underwent comprehensive ophthalmic assessment, including retinal imaging and electrodiagnostic testing. Developmental and systemic findings were also recorded. Molecular genetic approaches, including targeted next-generation sequencing, autozygosity mapping, and apex microarray, were tried to reach a diagnosis; all participants were mutation negative. Whole-exome sequencing or whole-genome sequencing was used to identify the causative variant. Biochemical profiling was conducted to confirm a CDG type I defect. Patient phenotype data were collected over the course of ophthalmic follow-up, spanning a period of 20 years, beginning March 20, 1997, through September 15, 2016. Main Outcomes and Measures: Detailed clinical phenotypes as well as genetic and biochemical results.
Results: The cohort consisted of 7 participants (5 females and 2 males) whose mean (SD) age at the most recent examination was 17.1 (3.9) years and who were all of South Asian ethnicity. Whole-exome sequencing and whole-genome sequencing identified the same homozygous SRD5A3 c.57G>A, p.(Trp19Ter) variant as the underlying cause of early-onset retinal dystrophy in each family. Detailed ocular phenotyping identified early-onset (aged ≤3 years) visual loss (mean [SD] best-corrected visual acuity, +0.95 [0.34] logMAR [20/180 Snellen]), childhood-onset nyctalopia, myopia (mean [SD] refractive error, -6.71 [-4.22]), and nystagmus. Six of the 7 patients had learning difficulties and psychomotor delay. Fundus autofluorescence imaging and optical coherence tomographic scans were abnormal in all patients, and electrodiagnostic testing revealed rod and cone dysfunction in the 5 patients tested. Conclusions and Relevance: Mutations in the SRD5A3 gene may cause early-onset retinal dystrophy, a previously underdescribed feature of the SRD5A3-CDG disorder that is progressive and may lead to serious visual impairment. SRD5A3 and other glycosylation disorder genes should be considered as a cause of retinal dystrophy even when systemic features are mild. Further delineation of SRD5A3-associated eye phenotypes can help inform genetic counseling for prognostic estimation of visual loss and disease progression.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28253385     DOI: 10.1001/jamaophthalmol.2017.0046

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  18 in total

1.  Biallelic variants in coenzyme Q10 biosynthesis pathway genes cause a retinitis pigmentosa phenotype.

Authors:  Neringa Jurkute; Francesca Cancellieri; Lisa Pohl; Catherina H Z Li; Robert A Heaton; Janine Reurink; James Bellingham; Mathieu Quinodoz; Georgia Yioti; Maria Stefaniotou; Marianna Weener; Theresia Zuleger; Tobias B Haack; Katarina Stingl; Carel B Hoyng; Omar A Mahroo; Iain Hargreaves; F Lucy Raymond; Michel Michaelides; Carlo Rivolta; Susanne Kohl; Susanne Roosing; Andrew R Webster; Gavin Arno
Journal:  NPJ Genom Med       Date:  2022-10-20       Impact factor: 6.083

2.  Expanding the FDXR-Associated Disease Phenotype: Retinal Dystrophy Is a Recurrent Ocular Feature.

Authors:  Neringa Jurkute; Priya D Shanmugarajah; Marios Hadjivassiliou; Jenny Higgs; Miodrag Vojcic; Iain Horrocks; Yann Nadjar; Valerie Touitou; Guy Lenaers; Roy Poh; James Acheson; Anthony G Robson; F Lucy Raymond; Mary M Reilly; Patrick Yu-Wai-Man; Anthony T Moore; Andrew R Webster; Gavin Arno
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-05-03       Impact factor: 4.799

3.  SSBP1 mutations in dominant optic atrophy with variable retinal degeneration.

Authors:  Neringa Jurkute; Costin Leu; Hans-Martin Pogoda; Gavin Arno; Anthony G Robson; Gudrun Nürnberg; Janine Altmüller; Holger Thiele; Susanne Motameny; Mohammad Reza Toliat; Kate Powell; Wolfgang Höhne; Michel Michaelides; Andrew R Webster; Anthony T Moore; Matthias Hammerschmidt; Peter Nürnberg; Patrick Yu-Wai-Man; Marcela Votruba
Journal:  Ann Neurol       Date:  2019-07-31       Impact factor: 11.274

4.  Loss-of-Function Mutations in the CFH Gene Affecting Alternatively Encoded Factor H-like 1 Protein Cause Dominant Early-Onset Macular Drusen.

Authors:  Rachel L Taylor; James A Poulter; Susan M Downes; Martin McKibbin; Kamron N Khan; Chris F Inglehearn; Andrew R Webster; Alison J Hardcastle; Michel Michaelides; Paul N Bishop; Simon J Clark; Graeme C Black
Journal:  Ophthalmology       Date:  2019-03-21       Impact factor: 12.079

5.  Phenogenon: Gene to phenotype associations for rare genetic diseases.

Authors:  Nikolas Pontikos; Cian Murphy; Ismail Moghul; Gavin Arno; Kaoru Fujinami; Yu Fujinami; Dayyanah Sumodhee; Susan Downes; Andrew Webster; Jing Yu
Journal:  PLoS One       Date:  2020-04-09       Impact factor: 3.240

Review 6.  Integrative and Analytical Review of the 5-Alpha-Reductase Type 2 Deficiency Worldwide.

Authors:  Rafael Loch Batista; Berenice Bilharinho Mendonca
Journal:  Appl Clin Genet       Date:  2020-04-14

Review 7.  Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm.

Authors:  Abdulmaged M Traish
Journal:  World J Mens Health       Date:  2020-03-20       Impact factor: 5.400

8.  Contribution of a Novel B3GLCT Variant to Peters Plus Syndrome Discovered by a Combination of Next-Generation Sequencing and Automated Text Mining.

Authors:  Justyna Totoń-Żurańska; Przemysław Kapusta; Magda Rybak-Krzyszkowska; Katarzyna Lorenc; Julita Machlowska; Anna Skalniak; Erita Filipek; Dorota Pawlik; Paweł P Wołkow
Journal:  Int J Mol Sci       Date:  2019-11-28       Impact factor: 5.923

9.  New variants and in silico analyses in GRK1 associated Oguchi disease.

Authors:  James A Poulter; Molly S C Gravett; Rachel L Taylor; Kaoru Fujinami; Julie De Zaeytijd; James Bellingham; Atta Ur Rehman; Takaaki Hayashi; Mineo Kondo; Abdur Rehman; Muhammad Ansar; Dan Donnelly; Carmel Toomes; Manir Ali; Elfride De Baere; Bart P Leroy; Nigel P Davies; Robert H Henderson; Andrew R Webster; Carlo Rivolta; Christina Zeitz; Omar A Mahroo; Gavin Arno; Graeme C M Black; Martin McKibbin; Sarah A Harris; Kamron N Khan; Chris F Inglehearn
Journal:  Hum Mutat       Date:  2020-11-30       Impact factor: 4.700

10.  Broadening INPP5E phenotypic spectrum: detection of rare variants in syndromic and non-syndromic IRD.

Authors:  Riccardo Sangermano; Iris Deitch; Virginie G Peter; Rola Ba-Abbad; Emily M Place; Erin Zampaglione; Naomi E Wagner; Anne B Fulton; Luisa Coutinho-Santos; Boris Rosin; Vincent Dunet; Ala'a AlTalbishi; Eyal Banin; Ana Berta Sousa; Mariana Neves; Anna Larson; Mathieu Quinodoz; Michel Michaelides; Tamar Ben-Yosef; Eric A Pierce; Carlo Rivolta; Andrew R Webster; Gavin Arno; Dror Sharon; Rachel M Huckfeldt; Kinga M Bujakowska
Journal:  NPJ Genom Med       Date:  2021-06-29       Impact factor: 8.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.